Skip to main content
VERTEX PHARMACEUTICALS INC / MA logo

VERTEX PHARMACEUTICALS INC / MA — Investor Relations & Filings

Ticker · VRTX ISIN · US92532F1003 LEI · 54930015RAQRRZ5ZGJ91 US Manufacturing
Open in API
Filings indexed 2,379 across all filing types
Latest filing 2024-04-11 M&A Activity
Country US United States of America
Listing US VRTX

About VERTEX PHARMACEUTICALS INC / MA

https://www.vrtx.com/

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to discover, develop, and commercialize transformative medicines for serious diseases. The company is a leader in the field of cystic fibrosis (CF), having developed multiple therapies that treat the underlying cause of the disease for a significant portion of patients. Beyond its focus on CF, Vertex is advancing a research and development pipeline that includes potential treatments for other serious conditions such as sickle cell disease, beta-thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, and type 1 diabetes. The company's strategy is centered on a deep understanding of human biology to address the root cause of illness.

Recent filings

Filing Released Lang Actions
SC TO-C Filing
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC by Vertex Pharmaceuticals Incorporated. It reports the entry into a material definitive agreement, specifically a merger agreement and related tender and support agreements. The document details the terms of the merger, conditions, and related agreements, which are typical contents of an M&A activity filing. The presence of the merger agreement, tender offer details, and related agreements clearly indicate this is an announcement related to a merger transaction. The document is not a full annual or quarterly report, nor is it a proxy statement or earnings release. It is a current report on a material event, specifically a merger announcement, which fits the M&A Activity category (TAR).
2024-04-11 English
SC TO-C Filing
Merger & Acquisition Classification · 100% confidence The document is a Schedule TO filing with the SEC, which is a Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934. It relates to a planned tender offer by Adams Merger Sub, Inc., a subsidiary of Vertex Pharmaceuticals, to acquire Alpine Immune Sciences, Inc. The document includes detailed information about the tender offer process, regulatory references, and forward-looking statements. It also references an investor presentation call transcript as an exhibit. The presence of Schedule TO and the context of a tender offer clearly indicate this is related to merger and acquisition activity. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length (9842 characters) and content confirm it is a substantive filing, not just an announcement or certification. Confidence is high due to explicit references to Schedule TO and tender offer details.
2024-04-11 English
SEC SCHEDULE 13G
Major Shareholding Notification
2024-04-10 English
SC TO-C Filing
Merger & Acquisition Classification · 100% confidence The document is a Schedule TO filing with the SEC, which is a Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934. It relates to a planned tender offer by Vertex Pharmaceuticals Incorporated for Alpine Immune Sciences, Inc. The text includes detailed information about the tender offer process, references to tender offer materials, and forward-looking statements about the transaction. It is not a full annual or quarterly report, audit report, or earnings release. It is clearly related to a merger and acquisition activity, specifically a tender offer. The presence of terms like 'Tender Offer Statement', 'Schedule TO', and detailed transaction description confirms this is an M&A related filing. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length and content confirm it is not a mere announcement but a substantive filing related to the tender offer transaction.
2024-04-10 English
VERTEX PHARMACEUTICALS INC - ARS
Annual Report
2024-04-04 English
VERTEX PHARMACEUTICALS INC - DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A Proxy Statement filed with the SEC, which is used to solicit shareholder votes and provide information for upcoming shareholder meetings. The text includes references to 'Proxy Statement,' 'Schedule 14A,' and 'Soliciting Material,' which are typical for Proxy Solicitation & Information Statements. The document length is short (1173 characters), and it is clearly a proxy filing rather than a full report or financial statement. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2024-04-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.